ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Oxfordbiotherapeutics
Oxford BioTherapeutics (OBT) is a biotechnology company focused on developing innovative antibody-drug conjugate (ADC) therapies for cancer. The company engages in discovery, biological evaluation, and preclinical studies to advance targeted cancer treatments, collaborating across multiple scientific disciplines and utilizing advanced technologies.
Headquarters
Oxford, England, United Kingdom
Company Size
11-50 employees
Founded
2004
Oxford BioTherapeutics is a biotechnology company focused on developing first‑in‑class oncology therapies. They pioneer targeted approaches including Antibody‑Drug Conjugates (ADCs), immuno‑oncology agents, T‑Cell Engagers (TCEs), and radiopharmaceuticals. The company advances a pipeline driven by translational science and strategic partnerships to accelerate delivery of novel cancer treatments to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Oxfordbiotherapeutics.
20% above the average for this role
Principal Scientist II - Pharmacology
Novartis
Scientist I, ADC Biochemistry
BioNTech
Principal Scientist - In-vitro Display
Eli Lilly and Company
Associate Principal Scientist, Discovery Oncology
MSD
Oncology Translational Medicine Lead Director
AstraZeneca
Principal Scientist, Translational Bioanalysis and Biomarkers
Nucleome